Concepedia

Maryna Kyselyova

MK

3

Publications

305

Citations

3

H-Index

2012

Active since

Affiliations

Janssen (United States)(Current)

Janssen (United Kingdom)

Janssen (Belgium)

Maryna Kyselyova is an author at Janssen (United States) specializing in hematology, oncology, and medicine.

Top concepts

MedicineOncologyHematologyHealthPathologyImmunologyPharmacologyImmunotherapyCancer ResearchPharmacotherapy

Publications per year

2012–2018

3

Publications

3

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Philippe Moreau, Ievgenii Karamanesht, Maryna Kyselyova et al. · Clinical Pharmacokinetics · 2012 · 84 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +6

Rows per page

1–3 of 3